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Abstract
Background: Current guidelines for lung cancer screening increased a positive scan
threshold to a 6 mm longest diameter. We extracted radiomic features from baseline
and follow‐up screens and performed size‐specific analyses to predict lung cancer
incidence using three nodule size classes (<6 mm [small], 6‐16 mm [intermediate],
and ≥16 mm [large]).
Methods: We extracted 219 features from baseline (T0) nodules and 219 delta features which are the change from T0 to first follow‐up (T1). Nodules were identified
for 160 incidence cases diagnosed with lung cancer at T1 or second follow‐up screen
(T2) and for 307 nodule‐positive controls that had three consecutive positive screens
not diagnosed as lung cancer. The cases and controls were split into training and test
cohorts; classifier models were used to identify the most predictive features.
Results: The final models revealed modest improvements for baseline and delta features when compared to only baseline features. The AUROCs for small‐ and intermediate‐sized nodules were 0.83 (95% CI 0.76‐0.90) and 0.76 (95% CI 0.71‐0.81) for
baseline‐only radiomic features, respectively, and 0.84 (95% CI 0.77‐0.90) and 0.84
(95% CI 0.80‐0.88) for baseline and delta features, respectively. When intermediate
and large nodules were combined, the AUROC for baseline‐only features was 0.80
(95% CI 0.76‐0.84) compared with 0.86 (95% CI 0.83‐0.89) for baseline and delta
features.
Conclusions: We found modest improvements in predicting lung cancer incidence
by combining baseline and delta radiomics. Radiomics could be used to improve current size‐based screening guidelines.
KEYWORDS
early detection, lung cancer screening, National Lung Screening Trial, quantitative imaging, Radiomics
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IN T RO D U C T ION

The National Lung Screening Trial (NLST) compared low‐
dose helical computed tomography (LDCT) vs standard chest
radiography for three annual screens and revealed a 20% relative reduction in lung cancer mortality among participants
screened with LDCT.1-3 In the LDCT arm, screen‐detected
incident lung cancers were found 2.7‐fold higher associated
with a stage shift from late stage to more early‐stage lung
cancers and exhibited improved 5‐year survival compared
with prevalence cancers diagnosed at baseline.3,4 Despite
the benefits associated with lung cancer screening, LDCT
imaging is associated with a high rate of detection of indeterminate pulmonary nodules (IPNs) of which only a fraction are diagnosed as lung cancer. In the NLST, 96.4% of
the positive LDCT screens were false positives/IPNs. Though
clinical guidelines5-7 provide for the evaluation and follow‐up
of nodules, there are no validated clinical decision tools to
predict lung cancer risk and probability of cancer development. Ideally, an efficient and accurate noninvasive approach
should be developed as a clinical decision tool for radiologists and pulmonologists to better manage nodules, especially IPNs, in the lung cancer screening setting.
Radiomics is the process of converting standard‐of‐care
digital medical images into quantitative image‐based feature
data that can be subsequently analyzed using conventional
biostatistics and machine learning methods.6 With high‐
throughput computing, it is now possible to rapidly extract
radiomic features from a region of interest that quantify size,
shape, intensity, and texture of the region of interest. As radiomic features are likely capturing biological and pathophysiology information of the region of interest,6 radiomics
have the potential to provide a rapid and accurate noninvasive
approach to better manage pulmonary nodules detected by
LDCT in the lung cancer screening setting.
In this study we conducted a nested case–control analysis
of the NLST, using training and test sets, to identify radiomic
features that are predictive of lung cancer incidence. We analyzed robust and reproducible radiomic features8 from baseline (T0)‐positive screens in the LDCT arm of the NLST to
identify radiomic models that predict lung cancer incidence in
the first (T1) and second (T2) follow‐up screening intervals.
Moreover, we also included delta radiomic features to determine whether changes in the nodules over time from T0 to T1
improve predicting lung cancer incidence. Current guideline
algorithms for managing LDCT‐detected solid and subsolid
nodules are largely based on size, specifically longest diameter. As recommended by the National Comprehensive Cancer
Network (NCCN)5 and the American College of Radiology
(ACR),6,7 the current cutoff size for assessing lung nodules
increased to 6 mm rather than the 4 mm originally used in the
NLST.2,3 Although this increase in threshold positivity has
been reported to decrease false‐positive results,7,9,10 decision

|

6341

support tools and lung cancer risk prediction are still lacking
for IPNs ≥6 mm. As such, we also performed size‐specific
analysis based on three size classes of the nodules: <6 mm
[small nodules], 6‐16 mm [intermediate‐sized nodules], and
≥16 mm [large nodules]. To our knowledge, this is one of
the first radiomic analyses in lung cancer screening to utilize
delta radiomic features (changes in radiomics over time) by
nodule size class to predict lung cancer incidence.

2
2.1

|

M ATERIAL S AND M ETHO D S

|

NLT study population

|

NLST CT screening results

|

Nested case–control study design

This research was approved by the Institutional Review
Board (Advarra, Inc, Columbia, MD, USA). Deidentified
data and LDCT images were obtained through the National
Cancer Institute (NCI) Cancer Data Access System
(CDAS).9 The NLST study design and main findings have
been described previously.2,3 Briefly, the NLST was a randomized multicenter trial comparing screening with LDCT
to CXR in high‐risk individuals. Eligibility criteria included
current or former smokers aged 55‐74 years with a minimum 30 pack‐years smoking history; former smokers had to
have quit within the past 15 years.

2.2

The NLST protocol defined a positive screening result as
one or more noncalcified nodules or masses measuring
≥4 mm in axial diameter or, less commonly, other abnormalities such as adenopathy or pleural effusion.2,3 Positive
screens were defined in the setting of abnormalities on baseline screens or abnormalities on follow‐up screens that were
new, stable, or that evolved with the latter demonstrating an
increase in nodule size, consistency, or other characteristic
potentially related to lung cancer. Participants with positive screening results received follow‐up recommendations;
trial‐wide guidelines for the management of positive screens
were developed, but were not mandated by protocol.
Negative screens were defined as CT scans with no abnormalities, minor abnormalities not suspicious for lung cancer,
or significant abnormalities not suspicious for lung cancer. In
this analysis, we did not include any participants who had a
negative screening result.

2.3

We performed a nested case–control study comprised of
screen‐detected incident lung cancers and matched nodule‐
positive controls from the LDCT arm of the NLST. Based
on the schema originally described in Schabath et al,4 the
screen‐detected incident lung cancers and nodule‐positive
controls are depicted in Figure 1A.
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A
T0 (Baseline)

T1 (first follow-up screen)

T2 (first follow-up screen)
T2 Incidence lung cancers
No. = 77

T1 Incidence lung cancers
No. = 83

T1 Screen
nodule [+]

T0 Screen
nodule [+]

T2 Screen
nodule [+]

T1 Nodule [+] controls
N = 172

T2 Nodule [+] controls
N = 135

B

FIGURE 1

2.3.1

Schematic representations of the nested case–control study design (A) and the radiomics and analytical workflow (B)

|

Lung cancer cases

|

Nodule‐positive controls

We identified 196 screen‐detected incident lung cancers who
had a baseline‐positive screen (T0) that was not diagnosed as
lung cancer and then were diagnosed at either the first (T1,
N = 104) or second follow‐up (T2, N = 92).

2.3.2

Using a 2:1 to nested case–control study design, we identified 392 LDCT screening participants who had three consecutive positive screens (T0 to T2) that were not diagnosed
as lung cancer. These NLST participants were designated as
nodule‐positive controls in the current analysis. The nodule‐
positive controls were frequency matched to the lung cancer
cases’ age at enrollment (±5 years), sex, race/ethnicity, and
smoking status. This study design minimizes the influence
of confounders between the cases and the controls. As such,
radiomic image features that differentiate cases and nodule‐
positive controls are not likely be attributed to external risk
factors.

2.3.3

|

Training and test sets

Based on the availability of complete LDCTs and inability
to verify the nodule/abnormality, the 192 lung cancer cases

were reduced to 160. Likewise, the original set of 392 nodule‐positive controls was reduced to 307. The lung cases
in cohort 1 were diagnosed at T1 and the lung cancer cases
in cohort 2 were diagnosed at T2. All of the nodule‐positive controls had a positive scan from T0 to T2 and never
developed lung cancer through T7 based on the available
NLST data. Cohort 1 was used as a training set and Cohort
2 as a test set.

2.4

|

Target lung nodule identification

The identification of target lung nodules has been previously
described.11 Briefly, two radiologists (YL and QL) reviewed
all LDCT images at both the lung window setting (width,
1500 HU; level, −600 HU) and the mediastinal window setting (width, 350 HU; level, 40 HU). The identification of
cancerous nodules among the screen‐detected incident lung
cancers was based on data provided by the NLST (ie, location
and size). As nodule location was not always available, the
senior radiologist (YL)11 identified the nodules and manually mapped each nodule from T0 to T1. The locations of all
nodules in this analysis are publically available in the TCIA
database (www.cancerimagingarchive.net). For NLST participants with multiple lung nodules, the largest nodule at
baseline (T0) and subsequent follow‐up nodule was used for
radiomic feature extraction.
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2.5 | CT segmentation, feature
extraction, and feature selection
The workflow of our radiomic pipeline12 and analyses is
depicted in Figure 1B. As previously described,11 a single‐
slick segmentation ensemble and subsequent feature extraction were performed using Definiens software (Definiens,
Inc, AG Cambridge, MA, USA). There were 219 features
extracted to quantify size, shape, location, and texture information of the pulmonary nodules.6 The complete list
of features used in our analyses has been previously described8 and was reduced to the most consistent features
based on our previous test/retest analyses. Additionally, we
used features from the same filter that based on Cohort 1
were found to be “stable” over time (denoted as C1 stable). C1 stable features were filtered using an analogous
approach to that for identifying RIDER stable features. For
RIDER stable features, two LDCT screenings were performed in a 15‐minute interval. For the C1 stable features
using the NLST subjects, we utilized T0 and T1 features
as the test/retest set. For each feature, we computed the
concordance correlation coefficient13 and dynamic range
and we selected as C1 stable features those which had values for both parameters greater than 0.95. Even though we
used a test/retest filter for initial feature selection, we built
models which were able to classify data with the most predictive number of features. For that purpose, we used feature selectors ReliefF (RfF) and Correlation‐based Feature
Selector (CFS). In each analysis, we selected the top 5 and
top 10 ranked features. Tables 2 and 4 present the performance statistics based on the models with the best AUROC.

2.6

|

Baseline and delta features

For all available cases and controls, we extracted radiomic
features from the T0 baseline screen and the T1 follow‐up
screen. To assess changes in nodules after an approximately
one‐year interval, we subtracted the T0 and T1 features to
generate delta features. For all patients in our analysis,
the median time from randomization to the T1 screen was
375 days (interquartile range = 360‐400 days). As such, the
time interval to the T1 screen is relatively consistent for all
subjects and eliminates the need to normalize the delta features with respect to time. In Tables 2 and 4, delta features
are denoted with a “∆” and baseline features are denoted with
“T0”.

2.7 | Size‐specific analyses: Splitting the
training and test sets on nodule size
Size‐specific analyses were performed based on the longest diameter (LD) of the T0 nodules. Current recommendations by
the NCCN and the American College of Radiology (ACR) have
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been increased for a positive scan to have a 6 mm longest diameter nodule5 rather than the 4 mm originally used in the NLST.3
As such, we performed size‐specific analyses using three nodule size classes: <6 mm [small nodules], 6‐16 mm [intermediate‐sized nodule], and ≥16 mm [large nodules]. Because there
were only 16 lung cancer cases and 7 nodule‐positive controls
in the large size class (≥16 mm), we combined the intermediate
and large class and repeated the analyses with two size classes:
<6 mm [small] and ≥6 mm [large].
For computing overall accuracy, sensitivity, and specificity, we summarized confusion matrices of each size group
and based on the result produce statistical parameters for the
model. Computation of the area under the receiver operating
characteristic (AUROC) uses a list of probabilities indicating
an instance belongs to a class. For computation of the “overall” AUROC, we merged probability lists for each size group
and produced the result on the final list.

2.8

|

Classifiers

Of the 219 features, there were 23 RIDER stable features and
37 C1 stable features. The C1 stable features are provided
in Table S1. Features marked with asterisk symbol in Table
S1 are used in RIDER stable feature set. Although we used
a test/retest filter initial selection, our goal was to identify
a model that is able to classify data with a small number of
features. Size‐specific nodules from Cohort 1 were utilized
to create the training dataset. For each training dataset, we
applied a feature selector in order to simplify resulting model
and remove noisy features. Selected features were used to
train a classifier and after training on a corresponding subset
of Cohort 2 used for testing. From multiple possible models, we selected the one which produces the highest AUROC.
For the feature selectors, we used ReliefF (RfF)14-16 and
Correlation‐based Feature Selector (CFS). For each feature
selector, we selected the top 5 and 10 ranked features to
identify highly predictive parsimonious models. One of the
benefits we gained from splitting datasets is the independent
usage of classifiers. For each subset, we applied the following classifiers:
•
•
•
•
•

Decision tree—J4817;
Rule‐based Classifier—JRIP18;
Naive Bayes19;
Support Vector Machine (SVM)19;
Random Forests.20

For the SVM classifier, we utilized a radial basis function as
a kernel and also a linear kernel. C and Gamma were found on
the training set using Grid Search. Performance statistics and
95% confidence intervals (CIs) were calculated for each model
including AUROC, accuracy, sensitivity, and specificity. All
the experiments were performed in Weka version 3.6.13.21

6344
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Study population characteristics of incident lung cancer cases and nodule‐positive controls by three nodule size classes
Lung cancer cases

Training set (C1)
Age, mean (SD)

Small
(<6 mm)
N = 14
66.4 (4.8)

Nodule‐positive controls

Intermediate
(6‐16 mm)
N = 53
63.4 (5.1)

Large
(≥16 mm)
N = 16
66.3 (5.6)

Small
(<6 mm)
N = 40
64.1 (5.2)

Intermediate
(6‐16 mm)
N = 125
64.0 (5.3)

Large
(≥16 mm)
N=7
62.4 (5.1)

Sex, N (%)
Male

9 (64.3)

27 (50.9)

8 (50.0)

23 (57.5)

76 (60.8)

4 (57.1)

Female

5 (35.7)

26 (49.1)

8 (50.0)

17 (42.5)

49 (39.2)

3 (42.9)

14 (100.0)

49 (92.5)

16 (100.0)

39 (97.5)

120 (96.0)

6 (85.7)

0 (0.00)

4 (7.6)

0 (0.00)

1 (2.5)

5 (4.0)

1 (14.3)

Former

8 (57.1)

24 (45.3)

10 (62.5)

16 (40.0)

63 (50.4)

5 (71.4)

Current

6 (42.9)

29 (54.7)

6 (37.5)

24 (60.0)

62 (49.6)

2 (28.6)

70.39 (27.8)

63.5 (23.7)

54.8 (13.1)

Race, N (%)
White
Non‐White
Smoking status, N (%)

Pack‐years, mean
(SD)

64.8 (28.3)

65.1 (25.1)

60.5 (19.2)

Family history of lung cancer
No

8 (57.1)

4 (79.3)

11 (68.8)

33 (82.5)

104 (83.2)

5 (71.4)

Yes

6 (42.9)

11 (20.8)

5 (31.3)

7 (17.5)

21 (16.8)

2 (28.6)

I

6 (42.9)

42 (79.3)

12 (75.0)

—

—

—

II

3 (21.4)

5 (9.4)

0 (0.0)

—

—

—

III

1 (7.1)

2 (3.8)

4 (25.0)

—

—

—

IV

4 (28.6)

3 (5.7)

0 (0.0)

—

—

—

NOS

0 (0.00)

1 (1.9)

0 (0.00)

—

—

—

Small cell

2 (14.3)

0 (0.0)

0 (0.0)

—

—

—

Adeno/BAC

8 (57.1)

35 (66.0)

14 (87.5)

—

—

—

Squamous cell

1 (7.1)

9 (17.0)

1 (6.3)

—

—

—

Other and NOS

3 (21.4)

9 (17.0)

1 (6.3)

—

—

—

Stage

Histology

Test set (C2)

Small
(<6 mm)
N = 19

Intermediate
(6‐16 mm)
N = 40

Large
(≥16 mm)
N = 18

Small
(<6 mm)
N = 20

Intermediate
(6‐16 mm)
N = 108

Large
(≥16 mm)
N=7

Age, mean (SD)

63.4 (5.2)

62.6 (4.4)

63.3 (5.4)

61.2 (4.6)

63.1 (4.8)

63.9 (3.5)

Male

12 (63.2)

21 (52.5)

10 (55.6)

5 (25.0)

67 (62.0)

5 (71.4)

Female

7 (36.8)

19 (47.5)

8 (44.4)

15 (75.0)

41 (38.0)

2 (28.6)

White

19 (100.0)

38 (95.0)

17 (94.4)

20 (100.0)

103 (95.4)

7 (100.0)

Non‐White

0 (0.0)

2 (5.0)

1 (5.6)

0 (0.0)

5 (4.6)

0 (0.0)

Former

9 (47.4)

19 (47.5)

9 (50.0)

9 (45.0)

47 (43.5)

4 (57.1)

Current

10 (52.6)

21 (52.5)

9 (50.0)

11 (55.0)

61 (56.5)

3 (42.9)

Pack‐years, mean
(SD)

61.3 (32.4)

62.2 (21.5)

66.9 (24.2)

62.8 (21.9)

60.2 (20.9)

59.4 (21.4)

Sex, N (%)

Race, N (%)

Smoking status, N (%)

(Continues)
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(Continued)

Test set (C2)

Small
(<6 mm)
N = 19

Intermediate
(6‐16 mm)
N = 40

Large
(≥16 mm)
N = 18

Small
(<6 mm)
N = 20

Intermediate
(6‐16 mm)
N = 108

Large
(≥16 mm)
N=7

Family history of lung cancer
No

13 (68.4)

34 (85.0)

12 (66.7)

18 (90.0)

91 (84.3)

5 (71.4)

Yes

6 (31.6)

6 (15.0)

6 (33.3)

2 (10.0)

17 (15.7)

2 (28.6)

I

10 (52.6)

28 (70.0)

16 (88.9)

—

—

—

II

3 (15.8)

1 (2.5)

0 (0.0)

—

—

—

III

3 (15.8)

7 (17.5)

0 (0.0)

—

—

—

IV

3 (15.8)

3 (7.5)

2 (11.1)

—

—

—

NOS

0 (0.0)

1 (2.5)

0 (0.0)

—

—

—

Small cell
carcinoma

3 (15.8)

1 (2.5)

0 (0.0)

—

—

—

Adenocarcinoma/
BAC

10 (52.6)

23 (57.5)

13 (72.2)

—

—

—

Squamous cell
carcinoma

4 (21.1)

6 (15.0)

1 (5.6)

—

—

—

Other and NOS

2 (10.5)

10 (25.0)

4 (22.2)

—

—

—

Stage

Histology

2.9 | Synthetic Minority
Oversampling Technique
Because of the imbalance of case and controls across the
various size classes, we also applied Synthetic Minority
Oversampling Technique (SMOTE)22 in the analyses.
SMOTE is an oversampling approach in which the minority
class is over‐sampled by creating “synthetic” examples rather
than by oversampling with replacement. To create a synthetic
instance, one example (nodule feature vector) is randomly
picked from minority class. For that example, five nearest
neighbors in the same class are chosen. Then, one of these
neighbors is randomly chosen. For each numeric feature, the
example and its chosen neighbor produce a line segment between the two features. A new synthetic instance represents a
randomly chosen point on the line segment for each feature.
The process repeats with a new example randomly chosen
until the desired number of instances is produced.

3

|

R E S U LTS

The study population characteristics for the three size classes
by the training and test sets of the lung cancer cases and nodule‐positive controls are presented in Table 1. None of the
study population characteristics were significantly different
between the training cohort and test cohort (Table S2) and, as
previously reported (Table 1 in11), none of the study population characteristics are significantly different between the lung

cancer cases and nodule‐positive controls. The final models
for the three nodule size classes (Table 2 and Figure 2A‐D)
generally revealed modest improvements in the performance
statistics for models with baseline and delta radiomic features
vs. models with only baseline radiomics. The AUROC for
small‐sized nodules was 0.83 (95% CI 0.76‐0.90) for baseline‐only radiomic features and 0.84 (95% CI 0.77‐0.90) for
baseline and delta features. For intermediate‐sized nodules,
the AUROC was 0.76 (95% CI 0.71‐0.81) for baseline‐only
radiomic features and 0.84 (95% CI 0.80‐0.88) for baseline
and delta features. For large‐sized nodules, the AUROC was
higher for baseline‐only radiomic features (AUROC = 0.86;
95% CI 0.75‐0.91) compared with baseline and delta features
(AUROC = 0.83; 95% CI 0.75‐0.91).
We also computed the overall AUROC (Table 2),
which included all nodule sizes, for baseline‐only features
(AUROC = 0.83; 95% CI 0.82‐0.86) and baseline and delta
features (AUROC = 0.86; 95% CI 0.83‐0.89). As such, we
had a higher AUROC and accuracy for the large‐sized nodule model (0.86) compared with the overall model (0.83).
When comparing the overall model to the intermediate‐
sized nodule model, the overall model had higher AUROC,
but the intermediate‐sized model had higher accuracy (0.76
vs 0.74) and specificity (0.92 vs 0.90). When comparing
the overall model to the small‐sized nodule model, the
AUROCs and specificities were identical for small‐sized
nodules. The overall AUROC for three size classes for
baseline and delta features was 0.86 (0.83‐0.89), which was
higher than the AUROCs for the three size‐specific models.

Baseline nodule
size

Small (<6 mm)

Small (<6 mm)

Small (<6 mm) with
SMOTE

Small (<6 mm) with
SMOTE

Intermediate
(6‐16 mm)

Baseline‐only

Baseline + Delta

Baseline‐only

Baseline + Delta

Baseline‐only

0.69 (0.57‐0.82)

0.84 (0.77‐0.90)

0.72 (0.59‐0.84)

0.76 (0.70‐0.81)

0.77 (0.69‐0.85)

0.86 (0.80‐0.92)

0.76 (0.71‐0.81)

T0 Mean [HU]
T0 Asymmetry
T0 MacSpic number of
T0 Number of pixels
T0 avgRLN
T0 Volume [cm]
T0 Volume (Pxl)
T0 Short axis × Longest diameter
T0 Longest diameter [mm]
T0 Circularity
T0 Mean [HU]
T0 Attached to pleural wall
∆ StdDev [HU]
T0 Asymmetry
T0 Circularity
T0 Roundness
T0 Relative border to pleural wall
T0 Relative border to lung
T0 Volume (Pxl)
T0 StdDev [HU]
T0 Is attached to pleural wall
T0 Mean [HU]
T0 Longest diameter
T0 Circularity
T0 Roundness

0.77 (0.65‐0.88)

0.59 (0.45‐0.72)

0.83 (0.76‐0.90)

T0 Mean [HU]
T0 Laws features L5 W5 L5
T0 Asymmetry
T0 StdDev [HU]
T0 Roundness
T0 Mean [HU]
T0 Is attached to pleural wall
∆ StdDev [HU]
T0 Asymmetry
T0 Circularity

Accuracy (95% CI)

AUROC (95% CI)

0.92 (0.88‐0.97)

0.95 (0.86‐1.04)

1.0 (1.0‐1.0)

0.90 (0.78‐1.0)

0.90 (0.78‐1.0)

Specificity (95%
CI)

  

(Continues)

0.30 (0.18‐0.42)

0.47 (0.27‐0.68)

0.53 (0.32‐0.73)

0.47 (0.27‐0.68)

0.26 (0.08‐0.44)

Sensitivity (95% CI)

|

Final models

Final models for best AUROC by nodule size with three size classes for baseline‐only features and baseline plus delta features

Features

TABLE 2
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Intermediate
(6‐16 mm)

Intermediate
(6‐16 mm) with
SMOTE

Intermediate
(6‐16 mm) with
SMOTE

Large (≥16 mm)

Baseline‐only

Baseline + Delta

Baseline‐only

Baseline nodule
size

(Continued)

Baseline + Delta

Features

TABLE 2

0.86 (0.75‐0.91)

T0 SD dist COG to border
T0 Volume [pix]
T0 Circularity
T0 Short axis × longest diameter
T0 Max dist COG to border
T0 Relative border to lung
T0 Laws features E5 E5 R5
T0 Longest diameter
T0 Roundness
T0 Volume [cm]

0.76 (0.77‐0.99)

0.86 (0.81‐0.91)

0.85 (0.81‐0.89)

∆ Number of pixels
∆ SD Dist COG to border [mm]
T0 MAX Dist COG to border [mm]
∆ Volume [cm ]
T0 Volume (Pxl)
∆ Short axis × longest diameter
T0 Circularity
∆ MAX Dist COG to border [mm]
∆ Mean [HU]
∆ avgRLN

0.80 (0.74‐0.85)

0.84 (0.80‐0.88)

0.82 (0.76‐0.87)

Accuracy (95% CI)

AUROC (95% CI)

0.77 (0.72‐0.82)

T0 Is Attached To Pleural Wall
T0 Mean [HU]
T0 Longest diameter [mm]
T0 Circularity
T0 Roundness
T0 Short axis × Longest diameter
T0 Relative border to lung
T0 Asymmetry
T0 Relative border to pleural wall
T0 StdDev [HU]

T0 Is attached to pleural wall
T0 Longest diameter
∆ max dist COG to border
T0 Mean [HU]
T0 Circularity

Final models

0.62 (0.28‐0.97)

0.97 (0.95‐1.0)

0.87 (0.82‐0.92)

0.95 (0.92‐0.99)

Specificity (95%
CI)

  

|
(Continues)

1.0 (1.0‐1.0)

0.55 (0.42‐0.68)

0.68 (0.55‐0.80)

0.37 (0.24‐0.50)

Sensitivity (95% CI)

CHEREZOV et al.
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0.86 (0.83‐0.89)

Overalla

Overalla

Overall with
SMOTEa

Overall with
SMOTEa

Baseline‐only

Baseline + Delta

Baseline‐only

Baseline + Delta

“Overall” includes all nodule sizes

a

0.83 (0.82‐0.86)

Large
(≥16 mm)—
SMOTE

Baseline + Delta

T0 Mean [HU]
T0 Laws features E5 E5 L5
T0 Relative border to lung
T0 Relative border to pleural wall
T0 Volume (Pxl)
∆ Short axis [mm]
T0 3D laws features L5 W5 L5
∆ Volume (Pxl)
T0 Attached to pleural wall
∆ avgRLN

0.87 (0.84‐0.90)

0.81 (0.78‐0.84)

0.80 (0.71‐0.89)

0.83 (0.78‐0.87)

0.81 (0.76‐0.85)

0.78 (0.74‐0.83)

0.74 (0.69‐0.79)

0.80 (0.66‐0.94)

0.80 (0.66‐0.94)

0.89 (0.82‐0.96)

T0 Mean [HU]
T0 Longest diameter [mm]
T0 Short axis × longest diameter
T0 Short axis [mm]
T0 StdDev [HU]

Large (≥16 mm)
with SMOTE

Baseline‐only

0.88 (0.77‐0.99)

0.83 (0.75‐0.91)

Accuracy (95% CI)

0.95 (0.92‐0.98)

0.87 (0.82‐0.92)

0.93 (0.90‐0.97)

0.90 (0.86‐0.95)

0.57 (0.18‐0.96)

0.43 (0.04‐0.82)

0.71 (0.36‐1.0)

Specificity (95%
CI)

0.61 (0.52‐0.70)

0.70 (0.61‐0.79)

0.53 (0.44‐0.63)

0.45 (0.36‐0.55)

0.89 (0.76‐1.02)

0.94 (0.85‐1.04)

0.94 (0.85‐1.0)

Sensitivity (95% CI)

|

T0 Mean [HU]
T0 Laws features E5 E5 L5
T0 Relative border to lung
T0 Relative border to pleural wall
T0 Volume [pxl]
∆ Short axis [mm]
T0 Laws features L5 W5 L5
∆ Volume [pxl]
T0 Is attached to pleural wall
∆ avgRLN

Large (≥16 mm)

AUROC (95% CI)

Baseline + Delta

Final models

Baseline nodule
size

(Continued)

Features

TABLE 2
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F I G U R E 2 AUROC figures for the final models for small nodules without SMOTE (A), small nodules with SMOTE (B), large nodules
without SMOTE (C), and large nodules with SMOTE (D)

However, the large‐sized nodule model had a higher accuracy than the overall model (0.88 vs 0.78). Likewise, the intermediate‐sized nodule model had a higher accuracy than
the overall model (0.80 vs. 0.78).
We also found when we applied the SMOTE method,
which over‐samples the minority class creating synthetic
minority class examples, some of the performance statistics
improved (Table 2).
Because there were only 16 lung cancer cases and 7 nodule‐positive controls with large nodules (≥16 mm), we combined the intermediate‐ and large groups and repeated the
analyses (Tables 3 and 4 and Figure 2A‐D). As such, when
the intermediate‐sized nodules and large nodules were combined into a single group (≥6 mm), the AUROC for baseline‐
only features was 0.80 (95% CI 0.76‐0.84) compared with an
AUROC of 0.86 (95% CI 0.83‐0.89) for baseline and delta
features. The AUROC for the overall model was identical for

the large‐sized nodule model; however, the large‐sized nodule model has higher accuracy and specificity. Figure 2Aa‐C
presents the AUROC plots for the final models for the small
nodules and large nodules with and without SMOTE.

4

|

DISCUSSION

While lung cancer screening with LDCT for high‐risk individuals has unequivocally demonstrated that early detection saves lives, the current screening strategy comes at the
identification of large numbers of indeterminate nodules and
limited clinical decision tools to manage nodules.23 As such,
we conducted a nested case–control analysis of the NLST
to identify radiomic‐based models that predict lung cancer incidence. We utilized training and test sets of incident
lung cancer cases and nodule‐positive controls to generate

6350
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TABLE 3
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Incident lung cancer cases and nodule‐positive controls by nodule size with by two nodule size classes
Lung cancer cases

Nodule‐positive controls

Training set (C1)

Small
(<6 mm)
N = 14

Large
(≥6 mm)
N = 69

Age, mean (SD)

66.4 (4.8)

64.1 (5.3)

Small
(<6 mm)
N = 40
64.1 (5.2)

Large
(≥6 mm)
N = 132
63.9 (5.3)

Sex, N (%)
Male

9 (64.3)

35 (50.7)

23 (57.5)

80 (60.6)

Female

5 (35.7)

34 (49.3)

17 (42.5)

52 (39.4)

14 (100.0)

65 (94.2)

39 (97.5)

126 (95.5)

0 (0.0)

4 (5.8)

1 (2.5)

6 (4.6)

Former

8 (57.1)

34 (49.3)

16 (40.0)

68 (51.5)

Current

6 (42.9)

35 (50.7)

24 (60.0)

64 (48.5)

70.3 (27.8)

61.5 (22.0)

Race, N (%)
White
Non‐White
Smoking status, N (%)

Pack‐years, mean
(SD)

64.8 (28.3)

64.8 (24.8)

Family history of lung cancer
No

8 (57.1)

53 (76.8)

33 (82.5)

109 (82.6)

Yes

6 (42.9)

16 (23.2)

7 (17.5)

23 (17.4)

I

6 (42.9)

54 (78.3)

—

—

II

3 (21.4)

5 (7.3)

—

—

III

1 (7.1)

6 (8.7)

—

—

IV

4 (28.6)

3 (4.4)

—

—

NOS

0 (0.00)

1 (1.5)

—

—

Small cell

2 (14.3)

0 (0.0)

—

—

Adeno/BAC

8 (57.1)

49 (71.0)

—

—

Squamous cell

1 (7.1)

10 (14.5)

—

—

Other and NOS

3 (21.4)

10 (14.5)

—

—

Stage

Histology

Test Set (C2)

Small
(<6 mm)
N = 19

Large
(≥6 mm)
N = 58

Small
(<6 mm)
N = 20

Large
(≥6 mm)
N = 115

Age, mean (SD)

63.4 (5.2)

62.8 (4.7)

61.2 (4.6)

63.2 (4.7)

Male

12 (63.2)

31 (53.5)

5 (25.0)

72 (62.6)

Female

7 (36.8)

27 (46.5)

15 (75.0)

43 (37.4)

Sex, N (%)

Race, N (%)
White

19 (100.0)

55 (94.8)

20 (100.0)

110 (95.7)

Non‐White

0 (0.0)

3 (5.2)

0 (0.0)

5 (4.4)

Smoking status, N (%)
Former

9 (47.4)

28 (48.3)

9 (45.0)

51 (44.4)

Current

10 (52.6)

30 (51.7)

11 (55.0)

64 (55.7)

Pack‐years, mean
(SD)

61.3 (32.4)

63.6 (22.3)

62.8 (21.9)

60.1 (20.9)
(Continues)
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(Continued)

Test Set (C2)

Small
(<6 mm)
N = 19

Large
(≥6 mm)
N = 58

Small
(<6 mm)
N = 20

Large
(≥6 mm)
N = 115

Family history of lung cancer
No

13 (68.4)

46 (79.3)

18 (90.0)

96 (83.5)

Yes

6 (31.6)

12 (20.7)

2 (10.0)

19 (16.5)

I

10 (52.6)

44 (75.9)

—

—

II

3 (15.8)

1 (1.7)

—

—

III

3 (15.8)

7 (12.1)

—

—

IV

3 (15.8)

5 (8.6)

—

—

NOS

0 (0.0)

1 (1.7)

—

—

Small cell carcinoma

3 (15.8)

1 (1.7)

—

—

Adenocarcinoma/
BAC

10 (52.6)

36 (62.1)

—

—

Squamous cell
carcinoma

4 (21.1)

7 (12.1)

—

—

Other and NOS

2 (10.5)

14 (24.1)

—

—

Stage

Histology

performance statistics of baseline‐only radiomic features vs.
the combination of time‐varying delta radiomic features and
baseline features. Additionally, analyses were conducted
across three nodule size classes. Overall, we found that combining delta radiomics with baseline radiomics generally
improved the performance statistics to predict lung cancer
incidence when compared to using only baseline radiomic
features. However, we note inconsistent results in some of
the performance statistics when comparing the overall models, which were not size‐specific, to the size‐specific models.
As such, our findings suggest there is a trade‐off in terms of
performance using nodule size‐specific models vs. an overall
model.
Previous studies have shown the utility of delta radiomic
in lung cancer prognostication and therapy response,24,25
and to the best of our knowledge, this is the first analysis to
consider delta radiomics in the lung cancer screening setting. The modest improvements by including delta features
with the baseline features suggest there were not substantial
time‐varying differences from the baseline screen (T0) to
the first follow‐up screen (T1) which occurred 12 months
later. In our previous work4 that evaluated the screening
histories and outcomes from T0 to T2 of the entire CT‐arm
of the NLST, there were 6921 nodule‐positive controls at
T0, then 4951 positive screens at T1 of which only 104
were diagnosed as lung cancer. As such, the majority of the
nodules were either stable at T1 (N = 4951 nodule‐positive
controls) or they resolved and were scored as a negative
screen T1 (N = 1488 negative screens). So, the observed

modest improvements in performance statistics of delta
radiomics in the NLST warrant their further evaluation in
other screening settings.
In our previous work using baseline‐only features in the
NLST,11 a random forest classifier identified a model of
23 features that could predict nodules that would be diagnosed as lung cancer 1 year after baseline with an AUROC
of 0.83 and 2 years after baseline with an AUROC of 0.75.
Our current analysis differed from the previous work11 in
many ways. First, the prior work identified a single model
based on the best accuracy using only baseline features. In
the current analysis, we included delta radiomics, generated
radiomics models by nodule class size, trained our models
to identify the features that achieved the best AUROCs, and
we applied a SMOTE approach since there was an imbalance of case and controls across the various size classes.
Additionally, to identify highly predictive parsimonious
models with fewer features that were previously identified
(23 features), we choose to identify models containing the
top 5 and 10 features. We focused on AUROC because
prior work demonstrated26 that AUROC is a better measure
than accuracy in the evaluation of learning algorithms by
demonstrating that AUROC is statistically consistent and
more discriminating than accuracy.
A novel and important aspect on our analyses was the radiomic models by nodule size class. Nodule size is a key
characteristic of malignancy whereby larger nodules have a
higher probability of being diagnosed as lung cancer.27 As
such, the management of nodules in current lung cancer

Baseline nodule size

Large (≥6 mm)

Large (≥6 mm)

Large (≥6 mm) with
SMOTE

Large (≥6 mm) with
SMOTE

Baseline‐only

Baseline + Delta

Baseline‐only

Baseline + Delta

0.80 (0.76‐0.84)

0.86 (0.83‐0.89)

0.79 (0.75‐0.83)

0.85 (0.82‐0.88)

T0 Mean [HU]
T0 Is attached to pleural wall
∆ Max dist COG to border
∆ Longest diameter
T0 Roundness
T0 Circularity
∆ Mean [HU]
T0 SD dist COG to border
T0 Longest diameter
T0 Max dist COG to border
T0 Mean [HU]
T0 Roundness
T0 Circularity
T0 Is Attached to pleural wall
T0 Longest diameter [mm]
T0 MAX Dist COG to border [mm]
T0 StdDev [HU]
T0 SD Dist COG to border [mm]
T0 3D laws features L5 W5 L5
T0 Relative border to lung
T0 Mean [HU]
T0 Attached to pleural wall
∆ MAX Dist COG to border [mm]
∆ Longest diameter [mm]
T0 Roundness
T0 Circularity
∆ Mean [HU]
T0 SD Dist COG to border [mm]
T0 Longest diameter [mm]
T0 MAX Dist COG to border [mm]

AUROC
(95% CI)

T0 Mean [HU]
T0 Roundness
T0 Circularity
T0 Is attached to pleural wall
T0 Longest diameter
T0 Max dist COG to border
T0 StdDev [HU]
T0 SD dist COG to border
T0 3D Laws features L5 W5 L5
T0 Relative border to lung

Final model

0.80 (0.75‐0.85)

0.73 (0.67‐0.78)

0.82 (0.77‐0.87)

0.75 (0.70‐0.80)

Accuracy
(95% CI)

Final models for best AUROC for large nodules (≥6 mm) for baseline‐only features and baseline plus delta features

0.87 (0.82‐0.92)

0.83 (0.78‐0.89)

0.93 (0.89‐0.97)

0.89 (0.85‐0.99)

Specificity
(95% CI)

  

(Continues)

0.66 (0.55‐0.76)

0.52 (0.41‐0.63)

0.60 (0.49‐0.71)

0.46 (0.35‐0.58)

Sensitivity
(95% CI)

|

Features

TABLE 4
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0.61 (0.52‐0.7)
0.88 (0.84‐0.93)
0.78 (0.74‐0.83)
Overall with
SMOTEa
Baseline + Delta

0.85 (0.82‐0.88)

0.52 (0.42‐0.61)
0.86 (0.81‐0.91)
0.74 (0.69‐0.79)
Overall with
SMOTEa
Baseline‐only

0.78 (0.75‐0.81)

0.57 (0.48‐0.67)

0.41 (0.32‐0.51)
0.90 (0.85‐0.94)

0.92 (0.89‐0.96)
0.8 (0.75‐0.84)
0.86 (0.83‐0.89)
Overalla
Baseline + Delta

0.72 (0.67‐0.77)
0.80 (0.76‐0.83)
Overalla
Baseline‐only

“Overall” includes all nodule sizes

a

TABLE 4

(Continued)

Final model

AUROC
(95% CI)
Baseline nodule size
Features

Accuracy
(95% CI)

Specificity
(95% CI)

Sensitivity
(95% CI)
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screening guidelines is largely based on size and shape of the
nodule.5-7 Certainly, reductions in false‐positive rates have
been reported7,9,10 by increasing the size threshold for a positive scan from 4 to 6 mm. Results from the Dutch‐Belgian
Lung Cancer Screening (NELSON) trial 28 reported that
small nodules (<5 mm) have a 0.4% probability of lung cancer while intermediate‐sized nodules [5‐10 mm] have nearly
3 times the probability (1.3%) and require additional risk
stratification. Large nodules [≥10 mm] have 15.2% lung cancer probability and receive an immediate diagnostic workup.
Because of the distribution of nodule sizes among the cases
and controls (Figure 3), we selected different nodule size
cut‐points. Importantly, we note that each size class yielded
different final models of radiomic features suggesting the
potential importance of size‐specific biomarkers to improve
nodule management.
Another novel approach and subsequent finding in our
analysis were the improvements of sensitivity and specificity when we applied SMOTE.29 Classification analyses using
class‐imbalanced data are biased in favor of the majority class,
and the bias is even larger for high‐dimensional data where the
number of variables greatly exceeds the number of samples.29
To address potential bias and imbalance, we applied SMOTE
as this is a popular oversampling method that was originally
proposed to improve random oversampling. In our analyses,
we found that SMOTE tended to have marginal influence on
the AUROCs; however, we observed consistent modest improvements in sensitivity and specificity when SMOTE was
utilized when compared to the same size class where SMOTE
was not utilized. This suggests SMOTE is not beneficial in improving discrimination classifiers, which has been previously
reported by Blagus and Lusa,29 but improves the performance
of the classifier in terms of sensitivity and specificity.
There are some limitations and some strengths of this analysis. Although Lung‐RADSTM categories10 are commonly
used in lung cancer screening, we opted to utilize categories
based on longest diameter size. However, using this nested
case–control approach, we did not have adequate representation across Lung‐RADSTM categories10 since the majority
of the nodules were between 6 and 16 mm. Nonetheless, our
analyses did demonstrate that nodule size‐specific models
may have utility in improving some performance statistics
compared with an overall model. Another potential limitation is the nested case–control design resulting in the modest
sample size. The nested design was utilized because it is not
feasible to segment and extract radiomic features on >4,000
T0‐ and T1‐positive scans. Although our radiomic pipeline is
well‐established12 and is efficient for studies on lung cancer
screening, lung cancer outcomes, and radiogenomics,11,30-36
nodule identification and segmentation is still a time‐consuming bottleneck. However, we are actively pursuing approaches for automated segmentation which will allow us to
segment and extract radiomic features on large numbers of
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FIGURE 3

CHEREZOV et al.

Histogram of longest diameter for the lung cancer cases and nodule‐positive controls for the training set (A) and test set (B)

LDCT scans. We acknowledge there were fewer lung cancer
cases in the training set and there was an imbalance across
size classes; however, training on a subset improved accuracy
and area under the AUROC to predict lung cancer incidence.
Another possible limitation is that unmeasured/unknown
cofounders may exist between the lung cancer cases and
nodule‐positive controls. However, we attempted to reduce
confounding between the lung cancer cases and nodule‐positive controls by matching on key demographic features.
Despite the modest aforementioned limitations, we applied a
rigorous training and testing analyses to identify informative,
parsimonious models that predict lung cancer incidence in
the lung cancer screening setting.
In conclusion, we demonstrated that the inclusion of
delta radiomic features improves the ability to classify
which lung nodules will be diagnosed as an incident lung
cancer more accurately than previous reports.37-41 At present, adjunct biomarkers are not currently used for lung
cancer screening, largely attributed to their early stage in
development.42 Published reports have found that blood‐
based and circulating biomarkers exhibited sensitivity values ranging from 40% to 91% and specificity values from
75% to 84%,43-45 with possible cancer detection capability
as early as 12‐29 months prior to a lung cancer diagnosis.46
But, a critical goal of biomarker research is to add value
to existing risk assessment standards, and the biomarker
should be designed to supplement the current diagnostic/
management tools.47 As such, radiomic‐based biomarkers
are attractive because they can be incorporated into the
current radiology workflow, are noninvasive, and can be
generated from standard‐of‐care images negating the requirement of additional laboratory‐based biomarkers.
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